As of 2025-07-03, the Intrinsic Value of Zealand Pharma A/S (ZEAL.CO) is (315.34) DKK. This ZEAL.CO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 364.40 DKK, the upside of Zealand Pharma A/S is -186.50%.
The range of the Intrinsic Value is (2,369.90) - (173.53) DKK
Based on its market price of 364.40 DKK and our intrinsic valuation, Zealand Pharma A/S (ZEAL.CO) is overvalued by 186.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (2,369.90) - (173.53) | (315.34) | -186.5% |
| DCF (Growth 10y) | (176.11) - (2,166.07) | (305.91) | -183.9% |
| DCF (EBITDA 5y) | (66.54) - (89.43) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (93.74) - (126.38) | (1,234.50) | -123450.0% |
| Fair Value | -83.43 - -83.43 | -83.43 | -122.89% |
| P/E | (146.84) - (135.16) | (138.49) | -138.0% |
| EV/EBITDA | (84.00) - (110.85) | (87.81) | -124.1% |
| EPV | (126.65) - (205.19) | (165.92) | -145.5% |
| DDM - Stable | (208.61) - (4,160.00) | (2,184.31) | -699.4% |
| DDM - Multi | (113.85) - (1,824.04) | (217.35) | -159.6% |
| Market Cap (mil) | 25,890.62 |
| Beta | 0.85 |
| Outstanding shares (mil) | 71.05 |
| Enterprise Value (mil) | 25,509.11 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.98% |
| Cost of Debt | 7.48% |
| WACC | 6.99% |